In this study, metformin, pioglitazone, and ethinylestradiol cyproterone all improved various clinical features and quality of life in Pakistani women with PCOS, though no drug significantly reduced hirsutism.
January 2025 in “American Journal of Translational Research” This study reported that the combination of EE-CPA and raloxifene effectively manages PCOS-related infertility, enhancing pregnancy outcomes through improvements in metabolism, sex hormones, ovarian function, and endometrial receptivity, without significantly increasing adverse effects.
11 citations
,
April 2017 in “The European Journal of Contraception & Reproductive Health Care” This review highlights that Cyproterone acetate combined with ethinylestradiol is highly effective for treating severe acne and hirsutism in women with hyperandrogenism, and it also provides benefits for cycle control and mood improvement, according to the analysis of 78 studies.
5 citations
,
July 2020 in “PubMed” This study found that EE/CPA and EE/DES were both effective in reducing hirsutism in patients with PCOS, with no additional benefit from adding low-dose metformin.
1 citations
,
March 2013 in “The European Journal of Contraception & Reproductive Health Care” This publication discusses the political rationale behind the French regulator ANSM's decision to withdraw Diane®-35 from the market, in response to health concerns associated with third-generation oral contraceptives.